Banzel Patent Expiration

Banzel is a drug owned by Eisai Inc. It is protected by 6 US drug patents filed from 2013 to 2014 out of which all have expired. Banzel's patents have been open to challenges since 15 May, 2015. Based on its patents and exclusivities, its generic launch date is estimated to be May 14, 2023. Details of Banzel's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(1 year, 4 months ago)

Expired
US6740669 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(1 year, 10 months ago)

Expired
US7750028

(Pediatric)

Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Apr, 2019

(5 years ago)

Expired
US8076362

(Pediatric)

Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Dec, 2018

(5 years ago)

Expired
US7750028 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Oct, 2018

(5 years ago)

Expired
US8076362 Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Jun, 2018

(6 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Banzel's patents.

Given below is the list of recent legal activities going on the following patents of Banzel.

Activity Date Patent Number
Patent litigations
Expire Patent 08 Aug, 2022 US7750028 (Litigated)
Maintenance Fee Reminder Mailed 21 Feb, 2022 US7750028 (Litigated)
Expire Patent 20 Jan, 2020 US8076362
Maintenance Fee Reminder Mailed 05 Aug, 2019 US8076362
Payment of Maintenance Fee, 8th Year, Large Entity 21 Dec, 2017 US7750028 (Litigated)
Post Issue Communication - Certificate of Correction 15 Sep, 2014 US7750028 (Litigated)
Recordation of Patent Grant Mailed 13 Dec, 2011 US8076362
Patent Issue Date Used in PTA Calculation 13 Dec, 2011 US8076362
Issue Notification Mailed 22 Nov, 2011 US8076362
Application Is Considered Ready for Issue 10 Nov, 2011 US8076362


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Banzel and ongoing litigations to help you estimate the early arrival of Banzel generic.

Banzel's Litigations

Banzel been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 22, 2003, against patent number US6740669. The petitioner , challenged the validity of this patent, with ROBERT PORTMANN et al as the respondent. Click below to track the latest information on how companies are challenging Banzel's patents.

Last updated on October 8, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6740669 April, 2003 Decision
(17 Nov, 2003)
ROBERT PORTMANN et al


FDA has granted some exclusivities to Banzel. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Banzel, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Banzel.

Exclusivity Information

Banzel holds 3 exclusivities. All of its exclusivities have expired in 2016. Details of Banzel's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2013
Orphan Drug Exclusivity(ODE) Nov 14, 2015
Pediatric Exclusivity(PED) May 14, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Banzel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Banzel's family patents as well as insights into ongoing legal events on those patents.

Banzel's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Banzel's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 14, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Banzel Generics:

Rufinamide is the generic name for the brand Banzel. 10 different companies have already filed for the generic of Banzel, with Lupin Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Banzel's generic

How can I launch a generic of Banzel before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Banzel's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Banzel's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Banzel -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
100 mg 14 Nov, 2012 1 17 Aug, 2022 14 Nov, 2022 Extinguished Deferred
200 mg and 400 mg 14 Nov, 2012 5 16 May, 2016 14 Nov, 2022 Eligible
40 mg/mL 16 Jun, 2014 1 14 Nov, 2022 Extinguished

Alternative Brands for Banzel

Banzel which is used for managing and treating epilepsy., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Abbvie
Depakote Er Used for managing and preventing seizures in epilepsy and sometimes used for treating migraine headaches.
Catalyst Pharms
Fycompa used for controlling seizures in patients with epilepsy.
Supernus Pharms
Trokendi Xr Used for managing epilepsy and preventing migraines.





About Banzel

Banzel is a drug owned by Eisai Inc. It is used for managing and treating epilepsy. Banzel uses Rufinamide as an active ingredient. Banzel was launched by Eisai Inc in 2008.

Approval Date:

Banzel was approved by FDA for market use on 14 November, 2008.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Banzel is 14 November, 2008, its NCE-1 date is estimated to be 15 May, 2015.

Active Ingredient:

Banzel uses Rufinamide as the active ingredient. Check out other Drugs and Companies using Rufinamide ingredient

Treatment:

Banzel is used for managing and treating epilepsy.

Dosage:

Banzel is available in the following dosage forms - suspension form for oral use, tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
200MG TABLET Prescription ORAL
400MG TABLET Prescription ORAL
40MG/ML SUSPENSION Prescription ORAL
100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL